Stock Track | Artivion Plunges 13.10% on Lowered 2026 Outlook and Endospan Acquisition Plans

Stock Track05-08

Artivion's stock experienced a significant 24-hour plunge of 13.10% during Thursday's trading session, reflecting a sharp negative reaction from investors.

The decline followed the company's first-quarter earnings release and concurrent announcements that prompted a downward revision of its financial outlook. Artivion lowered its full-year 2026 revenue guidance to a range of $480 million to $496 million, down from its previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA outlook to $100 million to $107 million.

Investor sentiment was further impacted by Artivion's disclosure of plans to acquire Endospan, the developer of the recently FDA-approved NEXUS Aortic Arch System. The acquisition involves a base purchase price of $175 million, with Artivion electing to pay entirely in cash, resulting in a net purchase price of approximately $135 million. Additionally, the company could pay up to $200 million in contingent consideration based on the future performance of Endospan's product. Management indicated that U.S. revenue from the NEXUS system is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious annual forecast.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124828063?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 10:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124828063","market":"sg","top_or_hot":-1,"title":"Stock Track | Artivion Plunges 13.10% on Lowered 2026 Outlook and Endospan Acquisition Plans","media":"Stock Track","content":"<p>Artivion's stock experienced a significant 24-hour plunge of 13.10% during Thursday's trading session, reflecting a sharp negative reaction from investors.</p><p>The decline followed the company's first-quarter earnings release and concurrent announcements that prompted a downward revision of its financial outlook. Artivion lowered its full-year 2026 revenue guidance to a range of $480 million to $496 million, down from its previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA outlook to $100 million to $107 million.</p><p>Investor sentiment was further impacted by Artivion's disclosure of plans to acquire Endospan, the developer of the recently FDA-approved NEXUS Aortic Arch System. The acquisition involves a base purchase price of $175 million, with Artivion electing to pay entirely in cash, resulting in a net purchase price of approximately $135 million. Additionally, the company could pay up to $200 million in contingent consideration based on the future performance of Endospan's product. Management indicated that U.S. revenue from the NEXUS system is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious annual forecast.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Artivion Plunges 13.10% on Lowered 2026 Outlook and Endospan Acquisition Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Artivion Plunges 13.10% on Lowered 2026 Outlook and Endospan Acquisition Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 10:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Artivion's stock experienced a significant 24-hour plunge of 13.10% during Thursday's trading session, reflecting a sharp negative reaction from investors.</p><p>The decline followed the company's first-quarter earnings release and concurrent announcements that prompted a downward revision of its financial outlook. Artivion lowered its full-year 2026 revenue guidance to a range of $480 million to $496 million, down from its previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA outlook to $100 million to $107 million.</p><p>Investor sentiment was further impacted by Artivion's disclosure of plans to acquire Endospan, the developer of the recently FDA-approved NEXUS Aortic Arch System. The acquisition involves a base purchase price of $175 million, with Artivion electing to pay entirely in cash, resulting in a net purchase price of approximately $135 million. Additionally, the company could pay up to $200 million in contingent consideration based on the future performance of Endospan's product. Management indicated that U.S. revenue from the NEXUS system is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious annual forecast.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AORT","symbol_name":"Artivion","start_time":0,"source_url":"","article_id":"1124828063","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124828063","pubTimestamp":1778208250,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Artivion's stock experienced a significant 24-hour plunge of 13.10% during Thursday's trading session, reflecting a sharp negative reaction from investors.The decline followed the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AORT":"Artivion"},"translate_title":"个股追踪|Artivion暴跌13.10%因下调2026年展望和Endospan收购计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":1},"content_text":"Artivion's stock experienced a significant 24-hour plunge of 13.10% during Thursday's trading session, reflecting a sharp negative reaction from investors.The decline followed the company's first-quarter earnings release and concurrent announcements that prompted a downward revision of its financial outlook. Artivion lowered its full-year 2026 revenue guidance to a range of $480 million to $496 million, down from its previous forecast of $486 million to $504 million. The company also reduced its adjusted EBITDA outlook to $100 million to $107 million.Investor sentiment was further impacted by Artivion's disclosure of plans to acquire Endospan, the developer of the recently FDA-approved NEXUS Aortic Arch System. The acquisition involves a base purchase price of $175 million, with Artivion electing to pay entirely in cash, resulting in a net purchase price of approximately $135 million. Additionally, the company could pay up to $200 million in contingent consideration based on the future performance of Endospan's product. Management indicated that U.S. revenue from the NEXUS system is expected to be negligible in 2026 ahead of a planned 2027 commercial launch, contributing to the more cautious annual forecast.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124828063","isCrawlerRequest":true}